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Tthe Watchman (Boston Scientiﬁc, Marlborough, MA) is as effective as warfarin for the
reduction the risk of stroke, systemic embolism and cardiovascular mortality in this
population. A new generation of Watchman FLX (WM-FLX) has been designed to
further improve implant performance. The key design changes in the WM-FLX
include an increased number of struts, an a traumatic closed distal end, and a reduced
length. The WM-FLX can be redeployed after either full or partial recapture. In
contrast, the CG-WM has to be replaced if a full recapture is needed. The present
study is aimed to evaluate the WM-FLX device in a canine LAA model.
METHODS AND RESULTS 20 dogs were used in the study. Under TEE at 0, 45, 90 and
135 views and x-ray guidance, the device was appropriately sized at the LAA ostium.
Device deployment was attempted in all animals; of which 100% of WM-FLX (12/12)
and 75% of CG-WM (6/8) were successfully deployed. Of the two unsuccessful im-
plants, one was due to pericardial effusion and the other was due to unfavorable
anatomy. All implanted animals survived to 45 or 90d. At termination, no thrombus
was observed upon gross examination. Histopathology showed all of the devices to be
well-seated in the LAA ostium at 45 and 90d, and covered by a layer of neo-endo-
cardial tissue.
CONCLUSION The next generation Watchman FLX device has improved delivery,
with fewer devices partial or full recaptures compared to the CG-WM. Furthermore,
the WM-FLX device resulted in a better seal with no leaks compared to the CG-WM,
though neither device showed residual leaks in excess of 2 mm. The healing response
in WM-FLX was comparable to CG-WM, and no evidence of a safety risk was identiﬁed
in either cohort at either time point.
Overall Implantation ParametersCG-WM WM-FLXDogs 6 12Total devices used 10 12Full recaptures required 4 2Partial recaptures 3 3Peri-device jet (<2mm) 2 0MITRAL VALVE
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Immediate In-hospital Complications of Percutaneous Transvenous Mitral
Commissurotomy in patients with Mitral Stenosis
Dr. Md.Touﬁqur Rahman, Afzalur Rahman, Abdullah Al Shaﬁ Majumder,
Syed Azizul Haque
National Institute of Cardiovascular Diseases, Dhaka, Dhaka, Bangladesh
BACKGROUND Rheumatic mitral stenosis is a very common problem in our popula-
tion having an incidence of 54 percent among rheumatic heart disease with a female
preponderance of 2:1. Percutaneous balloon mitral commissurotomy is appealing
because the mechanism of valve dilation closely parallels the mechanism of surgical
mitral commissurotomy. The technique of balloon mitral commissurotomy has
evolved rapidly, with improvements in balloons, guide wires, and the application of
double-balloon techniques. So, we aimed to assess the immediate in-hospital com-
plications of percutaneous transvenous mitral commissurotomy (PTMC) in patients
with symptomatic moderate to severe rheumatic mitral stenosis in our population.
METHODS : A prospective study was done in National Institute of Cardiovascular
Diseases, Dhaka, Bangladesh and Al- Helal Heart Institute, Mirpur, Dhaka during the
period of August 2003 to June 2014. Nine hundred and ninety (990) patients with
rheumatic mitral stenosis who underwent PTMC were evaluated clinically, by echo-
cardiography and by catheter during and after procedure.
RESULTS After PTMC mean mitral valve area increased from 0.83  0.11 cm2 to 1.76 
0.27 cm2 as measured by echocardiography. Mitral valve gradient reduced to 11.63 
4.15 mm Hg from 28.46  03.94 mm Hg after PTMC. Mean left atrial pressure as
recorded by catheter before PTMC was 30.99  08.37 mm Hg while after PTMC it was
13.81  06.28 mm Hg. There was no procedural death. There were 4 patients in-
hospital death. 2 patients died from massive CVD after PTMC. 1 patient died from
renal failure and electrolyte imbalance, 1 patient died from multisystem organ failure
due to sepsis unrelated to PTMC. There were 2þ mitral regurgitation in 3 patients or
3þ post PTMC mitral regurgitation in 1 patient as assessed by left ventriculography.
There was no A-V block during or after PTMC.
Pericardial tamponade occurred in 5 patients post procedure and those patients
were successfully treated with pericardiocentesis in the catheterization laboratory
under echo guidance and PTMC was completed successfully. Thromboembolic events
occurred in 04 patients and in 2 patients massive CVD and in 2 patients TIA. Left to
right shunt (ASD) occurred in 30 patients.
Local vascular complications like pain, hemorrhage, hematoma occurred in 69
patients.
CONCLUSION PTMC is a very effective and safe procedure at relieving the hemody-
namic effects of rheumatic mitral stenosis. Complications during the procedure was
very few.CRT-820
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Percutaneous mitral balloon valvotomy (PMBV) has emerged as an alternative to
surgical treatment of mitral stenosis.
OBJECTIVES To identify the independents predictors of death and combined events
(death, new mitral balloon valvotomy, or mitral valve surgery) in long-term follow-up
of patients undergoing PMBV.
METHODS From 1987 to 2013 a total of 312 patients were followed-up 54.031.0 (1 to
126) months. The techniques were the single-balloon (84.4%), Inoue-balloon (13.8%),
and double-balloon techniques (1.7%). The total group was divided in two: echocar-
diographic score >8 and  8 points groups. Multivariate Cox regression analysis were
performed to identify independent risk factors of long-term survival and event free
survival.
RESULTS The mean age were 38.012.6 years old (range, 13 to 83). Before the pro-
cedure, 84,42% patients had echo score  8, and 15.57% score> 8. Females comprised
85%, and 84% patients were in sinus rhythm. During follow-up, survival of the total
group was 95.5%, echo score group  8 was 98.0% and echo score > 8 was 82.2%
(p<0.0001), whereas combined event-free survival was 83.4%, 86.1%, and 68.9%,
respectively (p 8 and the presence of severe mitral valve regurgitation during the
procedure. The predictors of combined events were a previous history of mitral
valvular commissurotomy, atrial ﬁbrillation, the presence of severe mitral valve
regurgitation during the procedure and post procedure mitral valve area < 1.5 m2.
CONCLUSION PMBV is an effective procedure. Survival was high, even higher in the
group with lower echocardiographic scores. Over 2/3 of the patients were event-free
at the end of follow-up. Independents predictors of survival were pre procedure echo
score  8 and the absence of severe mitral valve regurgitation during the procedure.
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Fully Percutaneous Transthoracic Left Atrial Access To Deliver Large
Interventional Devices
Toby Rogers, Kanishka Ratnayaka, William Schenke, Merdim Sonmez, Ozgur Kocaturk,
Jonathan Mazal, Marcus Chen, Anthony Faranesh, Robert Lederman
NHLBI, National Institutes of Health, Bethesda, MD
BACKGROUND Investigational transcatheter replacement mitral valves are bulky
devices requiring large caliber access ports. An access route (Fig 1A) that does not
impact left ventricular (LV) function could simplify device engineering and improve
patient outcomes. We hypothesized that by deﬂating a lung, it is possible to access
the left atrium (LA) through the posterior chest wall, and close the LA port using off-
the-shelf nitinol closure devices.
METHODS LA access was obtained in 2 large animal models under realtime MR (8
swine and 2 sheep) or X-ray ﬂuoroscopy (2 swine). A drain was inserted into the left
pleural space to insufﬂate with CO2 and displace the lung (arrow, Fig 1B). A needle
was introduced through the chest wall (Fig 1C) and into the LA posteriorly (Fig 1D). A
large (18Fr) sheath (arrow, Fig 1E-F) was advanced into the LA over a stiff wire. The
sheath was withdrawn and the LA puncture was closed with a nitinol closure device
(arrow, Fig 1G). Animals were re-imaged 7days later.
RESULTS Pleural access, left lung deﬂation, LA access and closure, and lung re-
inﬂation was successful in all 12 animals. There were no peri-procedural complica-
tions or mortality. After 7days, MRI conﬁrmed stable position of the LA closure device
in all (arrow, Fig 1H), only one pericardial effusion was observed and superﬁcial
wounds healed well (Fig 1I).
CONCLUSION Fully percutaneous MR guided direct LA access with large sheaths is
feasible in swine and sheep, providing access to the mitral valve without injuring the
LV myocardium. The LA port can be safely closed using off-the-shelf nitinol closure
devices. This technique could provide a simple and safe access route for transcatheter
mitral valve interventions.






















Support System of Bioprosthetic Valves With A Heart Shape Commissural Post
Efstathios Andreas Agathos
Athens Medical Center, Filothei-Athens, Greece
BACKGROUND Bioprosthetic valves fail due to torn leaﬂets as a result of increased
forces applied on the commissural posts during the cardiac cycle. To face this problem
a novel Support System (stent) with large openings at the Commissural posts made
from acetal copolymer (POM-C) or Titanium has been developed. The hydrodynamic
performance and durability of bioprosthetic valves constructed using this stent went
under evaluation.
METHODS This stent was initially designed to accommodate aortic and pulmonary
valves derived from marine mammal origin (Phoca Groelandica), showing excellent
hydrodynamic performance when tested in a steady ﬂow system. The same stent was
used to create three trileaﬂet composite porcine valves of 23mm (titanium), 27mm
and 31mm (POM-C) in diameter and one 25mm (titanium) bovine pericardial valve
wrapped around the stent. All valves were tested in a steady ﬂow system. The three
porcine valves underwent fatigue accelerating testing to deﬁne their long term
durability.
RESULTS For the porcine valves the peak pressure was measured as 12.5mmHg,
9.1 mmHg and 7.3mmHg for the 23mm, 27mm and for the 31mm valve respectively.
The 25mm pericardial valve showed a peak pressure of 5.5mmHg. The durability test
showed valve deterioration after 225x106cycles for the 23mm, 265x106 cycles for the
27mm and 240x106 cycles for the 31 mm, values far above the passing standards
according to ISO/DIS 5840.
CONCLUSION This novel stent for bioprosthetic valves offers excellent hydrodynamic
performance for a variety of biological issues tested and above the standards long
term durability, possibly due to the amelioration of forces applied on the commissural
posts during the cardiac cycle.
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Transcatheter Extra-Cardiac Tricuspid Annuloplasty
Toby Rogers, Kanishka Ratnayaka, Merdim Sonmez, Dominique Franson,
William Schenke, Jonathan Mazal, Ozgur Kocaturk, Marcus Chen, Anthony Faranesh,
Robert Lederman
NHLBI, National Institutes of Health, Bethesda, MD
BACKGROUND We designed and built a device that is positioned along the atrio-
ventricular groove in the pericardial space and tightened to modify the geometry of
the tricuspid annulus to treat functional tricuspid regurgitation. The device is
delivered to the pericardial space from within via trans-atrial puncture.
METHODS 15 swine, including 3 with dilated right heart and functional tricuspid
regurgitation, underwent extra-cardiac tricuspid annuloplasty. The pericardial spaceis accessed with large (12-14Fr) sheaths from a femoral vein, through the right atrium
and by puncture through the right atrial appendage. A self-orienting nitinol
compression device is then deployed around the atrioventricular groove and tight-
ened to exert compressive force to the free-wall of the tricuspid annulus. The atrial
puncture site is closed with an off-the-shelf nitinol closure device.
RESULTS In all 15 animals, trans-atrial pericardial access was uncomplicated and the
device was delivered successfully. Tricuspid septal-lateral and antero-posterior di-
mensions, annular area and perimeter were reduced by 49%, 31%, 59% and 24%
(p<0.001) respectively. Tricuspid leaﬂet coaptation length was increased by 53%
(p<0.001). The degree of annuloplasty correlated closely with the tension delivered
to the device (r2¼0.94, p<0.001). Coronary artery compression was not observed in
any animal, but a bridge-shaped protection element can be positioned over an un-
derlying vessel to deﬂect compressive force. 9 animals were survived for mean
9.7days and tricuspid geometric changes were maintained. In the 3 animals with
functional tricuspid regurgitation, severity of regurgitation by intracardiac echocar-
diography was reduced. Small pericardial effusions were observed immediately post-
procedure but had completely resolved at follow-up. Post-mortem examination
demonstrated ﬁbrotic encasement of the device along the atrioventricular groove and
no tissue erosion. There was no evidence of pericarditis or adhesions between
visceral and parietal pericardial layers.
CONCLUSION This is theﬁrst extra-cardiac structural intervention performed fromwithin
via trans-atrial puncture. The degree of tricuspid annuloplasty achieved is comparable to
current surgical techniques. The trans-atrial pericardial access port is safely closedwith off-
the-shelf devices, with no evidence of cardiac tamponade in swine.
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Does Angio-Seal Have a Role in Femoral Vascular Closure Following
Transcatheter Aortic Valve Replacement?
Sarkis Kiramijyan, Marco A. Magalhaes, Edward Koifman, Ricardo O. Escarcega,
Nevin C. Baker, Rebecca Torguson, Michael J. Lipinski, Hideaki Ota, Smita I. Negi,
Romain Didier, Thibault Lhermusier, Won Yu Kang, Wenjie Tian, Petros Okubagzi,
William O. Suddath, Itsik Ben-Dor, Lowell F. Satler, Augusto D. Pichard,
Ron Waksman
BACKGROUND Femoral access closure post transcatheter aortic valve replacement
(TAVR) remains challenging. The Perclose ProGlide (PP) device has been utilized in a
dual pre-close strategy; however, failure of this technique occurs in approximately
10% of cases. This study examined the utility of Angio-Seal (AS) in selected cases
where hemostasis is not achieved with the dual PP alone.
METHODS Patients who received a percutaneous transfemoral TAVR with the use of
at least two PP and, given residual bleeding, subsequently received one AS device,
were included. This cohort was divided into two groups: a success group (full ho-
meostasis with two PP and one AS), and a failure group (required additional in-
terventions). The baseline and procedural characteristics, in-hospital VARC-2 major
and minor vascular access site and bleeding complications, change in hemoglobin
of 3 g/dL, and blood transfusions were compared.
RESULTS A total of 169 patients (57% male, mean 83.7 years) underwent femoral
closure with at least two PP followed by one AS. Complete hemostasis was obtained in
140 (83%) cases (Table). In the failure group, there were higher rates of hypertension
(systolic aortic pressure 19228 vs. 12918 mmHg, p¼0.015 and diastolic aortic
pressure 6811 vs. 4215 mmHg, p¼0.050).
CONCLUSIONS The utility of the AS technique when a pre-close PP strategy fails in
patients with difﬁculty in femoral hemostasis after TAVR is feasible. Even when this
strategy fails, hemostasis is achieved with conventional techniques without requiring
surgery.CharacteristicsSuccess Group With
Angio-Seal (n[140)Failure Group With
Angio-Seal (n[29) p-ValueManual compression 0% (0/140) 14% (4/29) p<0.001Additional closure device(s)
prior to Angio-Seal0% (0/140) 7% (2/29) p¼0.020Balloon cross-over technique 15% (20/137) 29% (8/28) p¼0.009
Total access site percutaneous
intervention7% (7/107) 21% (6/28) p¼0.028Access site surgical intervention 3% (3/107) 0% (0/29) p¼1.000
Decrease in hemoglobin of 3 g/dL 8% (9/107) 8% (2/25) p¼1.000
VARC-2 major and minor vascular
complications16% (22/133) 30% (8/27) p¼0.174VARC-2 major and minor bleeding
complications11% (14/132) 15% (4/28) p¼0.220Post-procedural blood transfusion 20% (27/135) 39% (11/28) p¼0.028
